Liaw Y F, Lin D Y, Chen T J, Chu C M, Sheen I S
Infection. 1984 Jul-Aug;12(4):248-50. doi: 10.1007/BF01645951.
Fifteen patients with HBsAg-positive, severe chronic active hepatitis, nine DNA polymerase (DNAP)-positive and six negative were treated with intravenous adenine arabinoside (Ara-A) in a dose of 10 mg/kg/day for five consecutive days during each of two consecutive weeks. Of the DNAP-positive patients, two responded with histological and clinical remission as well as permanent loss of DNAP. However, histological and clinical remission were also observed in patients with unsatisfactory DNAP response and even in DNAP-negative patients. It is suggested that, in addition to its antiviral effect, Ara-A might have another mechanism, such as immunosuppression, that induced histological and clinical remission. Alternatively, the discrepancy of response might relate to the natural course of chronic type B hepatitis. Accordingly, controlled trial is mandatory for assessing the effect of Ara-A or any other agent in the treatment of chronic type B hepatitis.
15例乙肝表面抗原（HBsAg）阳性的重度慢性活动性肝炎患者，其中9例DNA聚合酶（DNAP）阳性，6例DNAP阴性，在连续两周的时间里，每周连续5天接受剂量为10mg/kg/天的静脉注射阿糖腺苷（Ara - A）治疗。在DNAP阳性患者中，有2例出现了组织学和临床缓解以及DNAP的永久性消失。然而，在DNAP反应不理想的患者甚至DNAP阴性患者中也观察到了组织学和临床缓解。提示除抗病毒作用外，Ara - A可能还有另一种机制，如免疫抑制，从而诱导组织学和临床缓解。或者，反应的差异可能与慢性乙型肝炎的自然病程有关。因此，必须进行对照试验以评估Ara - A或任何其他药物治疗慢性乙型肝炎的效果。
